Miro1 deficiency in amyotrophic lateral sclerosis by Fan Zhang et al.
ORIGINAL RESEARCH
published: 26 May 2015
doi: 10.3389/fnagi.2015.00100
Miro1 deficiency in amyotrophic
lateral sclerosis
Fan Zhang 1,2, Wenzhang Wang 1, Sandra L. Siedlak 1, Yingchao Liu 2, Jun Liu 3, Keji Jiang 4,
George Perry 5, Xiongwei Zhu 1 and Xinglong Wang 1*
1 Department of Pathology, Case Western Reserve University, Cleveland, OH, USA, 2 Department of Neurosurgery,
Shandong Provincial Hospital, Shandong University, Jinan, China, 3 Department of Neurology and Institute of Neurology,
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4 East China Sea Fisheries Research
Institute, Chinese Academy of Fishery Sciences, Shanghai, China, 5 College of Sciences, University of Texas at San Antonio,
San Antonio, TX, USA
Edited by:
Cheng-Xin Gong,
New York State Institute for Basic
Research in Developmental
Disabilities, USA
Reviewed by:
P. Hemachandra Reddy,
Texas Tech University, USA
Xuemin Xu,
The University of Tennessee, USA
*Correspondence:
Xinglong Wang,
Department of Pathology, Case
Western Reserve University, 2103
Cornell Road, Cleveland, OH 44106,
USA
xinglong.wang@case.edu
Received: 17 April 2015
Accepted: 11 May 2015
Published: 26 May 2015
Citation:
Zhang F, Wang W, Siedlak SL, Liu Y,
Liu J, Jiang K, Perry G, Zhu X and
Wang X (2015) Miro1 deficiency in
amyotrophic lateral sclerosis.
Front. Aging Neurosci. 7:100.
doi: 10.3389/fnagi.2015.00100
Proper transportation of mitochondria to sites with high energy demands is critical for
neuronal function and survival. Impaired mitochondrial movement has been repeatedly
reported in motor neurons of amyotrophic lateral sclerosis (ALS) patients and indicated
as an important mechanism contributing to motor neuron degeneration in ALS. Miro1,
a RhoGTPase also referred to as Rhot1, is a key regulator of mitochondrial movement
linking mitochondria and motor proteins. In this study, we investigated whether the
expression of Miro1 was altered in ALS patients and ALS animal models. Immunoblot
analysis revealed that Miro1 was significantly reduced in the spinal cord tissue of
ALS patients. Consistently, the decreased expression of Miro1 was also noted only
in the spinal cord, and not in the brain tissue of transgenic mice expressing ALS-
associated SOD1 G93A or TDP-43 M337V. Glutamate excitotoxicity is one of the major
pathophysiological mechanisms implicated in the pathogenesis of ALS, and we found
that excessive glutamate challenge lead to significant reduction of Miro1 expression
in spinal cord motor neurons both in vitro and in mice. Taken together, these findings
show Miro1 deficiency in ALS patients and ALS animal models and suggest glutamate
excitotoxicity as a likely cause of Miro1 deficiency.
Keywords: amyotrophic lateral sclerosis, Miro1, mitochondrial transport, SOD1, TDP-43, glutamate excitotoxicity,
neurodegeneration
Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most common motor neuron diseases
characterized by progressive neurodegeneration of motor neurons in the brainstem and spinal
cord (Rowland and Shneider, 2001). The vast majority of ALS cases, referred to as sporadic ALS
(sALS), are not genetically transmitted and their causes remain enigmatic. 5–10% of ALS cases
are familial (fALS), of which most are associated with repeat expansions of the C9ORF72 gene
or mutations in genes encoding copper–zinc superoxide dismutase (SOD1), TAR DNA binding
protein 43 (TDP-43) or fused in sarcoma (FUS; Al-Chalabi et al., 2012). The cellular and molecular
mechanisms underlying motor neuron loss in both fALS and sALS are unknown, and effective
treatments are extremely limited.
Unlike any other cell type, neurons especially motor neurons with extended axons and dendrites,
are highly dependent on mitochondrial trafficking for survival, because synaptic transmission
and ion channel activity in distal synaptic terminals are all great energy taxing processes
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(Kann and Kovács, 2007), and mitochondria need to be
efficiently transported to these sites with high metabolic
requirement (Sheng, 2014). Interestingly, accumulation
of mitochondria was reported in the proximal axons of
motor neurons of ALS patients, indicating the possible
impairment of mitochondrial transport (Sasaki and Iwata,
1996). Consistently, impaired mitochondrial movement and
altered mitochondrial distribution were noted in motor
neurons expressing ALS-associated mutant SOD1 G93A or
TDP-43 M337V in vitro and in mice (De Vos et al., 2007;
Bilsland et al., 2010; Wang et al., 2013; Magrané et al.,
2014). Despite expanding evidence for the important role
of mitochondrial trafficking deficits in the pathogenesis of
ALS (Shi et al., 2010), the underlying mechanism is still
not clear.
Mitochondria are transported bidirectionally in neurites
along microtubules for fast movement and along actin
filaments for slow movement via different motor-adaptor
complexes. In axons with uniform plus-end-out microtubules,
mitochondrial anterograde transport is driven by kinesin
motors whereas retrograde movement is controlled by dynein
motors (Schwarz, 2013). Microtubules in dendrites have
mixed orientation, therefore mitochondria can move in
either the anterograde or the retrograde direction (Sheng and
Cai, 2012). Motor proteins are usually indirectly linked to
mitochondria by Miro1-Milton adaptor complex, in which
Miro1 is the only known mitochondrial outer membrane
protein directly coupling mitochondria and motor-adaptor
complexes (Schwarz, 2013). Interestingly, a most recent
study in mice found that motor neurons are vulnerable to
Miro-1 ablation, and this Miro1 deficiency is sufficient to
specifically cause motor neuron degeneration and symptoms
of motor neuron diseases (Nguyen et al., 2014). Since ALS
patients and ALS experimental models display impaired
mitochondrial movement, here we sought to investigate
whether the expression of Miro-1 is altered in patients and
experimental models of ALS, the most common motor neuron
disease.
Materials and Methods
Embryonic Primary Motor Neuron Isolation and
Culture
Timed pregnant Sprague–Dawley rats from Charles River were
sacrificed following the protocol approved by the Institutional
Animal Care and Use Committee (IACUC) at Case Western
Reserve University. E13–15 rat embryos were obtained and
primary motor neurons were isolated as described (Wang et al.,
2015). Taken briefly, spinal cords were dissected out in L15
medium without phenol red (Invitrogen) and stored in 2%
B27 (Invitrogen) supplemented Hibernate E. After the removal
of dorsal root ganglia and the meninges, spinal cords were
digested in 0.25% trypsin for 15 min at room temperature
followed by Optiprep (Sigma) gradient centrifugation. Glia cells
were cultured in Neurobasal medium (Invitrogen) supplemented
with 2% B27 (Invitrogen) and 1% GlutaMax (Invitrogen) to
obtain glia-conditioned media. After seeding with Neurobasal
medium (Invitrogen) supplemented with 2% B27 (Invitrogen),
1% GlutaMax (Invitrogen) and 1% penicillin–streptomycin,
motor neurons were cultured in glia-conditioned medium
supplemented with 2% horse serum (Sigma), and 10 ng/ml each
BDNF, CNTF, and GDNF (Peprotech). The culture medium
was half-changed every 3 days. Glia cells or motor neurons
were cultured at 37◦C in a humidified 5% CO2 containing
atmosphere.
Western Blot Analysis, Antibodies and Chemicals
Tissues or culture motor neurons were lysed with 1XCell Lysis
Buffer (Cell Signaling Technology, Beverly, MA, USA), plus
1 mM phenylmethylsulfonyl fluoride (Sigma) and Protease
Inhibitor Cocktail (Sigma). Equal amounts of total protein
extract (10 ug) were resolved by sodium dodecyl sulfate
Polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to Immobilon-P (Millipore). Following blocking with 10%
non-fat dry milk, primary and secondary antibodies were
applied and the blots developed with Immobilon Western
Chemiluminescent HRP Substrate (Millipore). Frozen
human thoracic spinal cord tissues from 6 age-matched
normal (age 58 3.8; sex, M:F = 5:1) and 8 patients with
sALS (age 57 3.9; sex, M:F = 6:2) were obtained from
NICHD (The Eunice Kennedy Shriver National Institute
of Child Health and Human Development) Brain and
Tissue Bank. B6SJL-Tg (SOD1∗G93A) 1Gur/J (SOD1G93A)
mice and C57BL/6-Tg (Prnp-TARDBP∗M337V) 4Ptrc/J
(TDP-43M337V) mice were obtained from the Jackson
Laboratory. Primary antibodies used included mouse anti-
RHOT1 for detecting Miro1 (Abnova), mouse anti-VDAC1
(Abcam), rabbit anti-TDP-43 (Proteintech), mouse anti-
human TDP-43 (Novus), rabbit anti-SOD1 (Santa Cruz),
mouse anti-actin (Millipore, Billerica, MA) and rabbit anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell
Signaling). Glutamate (Sigma) and MK-801 (Tocris) were also
obtained.
Immunocytochemistry of Human Spinal Cord
Formalin fixed human spinal cord tissues obtained postmortem
from University Hospitals of Cleveland and the NICHD Brain
and Tissue Bank were paraffin embedded and sectioned and
immunocytochemistry was performed by the peroxidase anti-
peroxidase protocol as described (Zhu et al., 2000). Taken
briefly, following immersion in xylene, hydration through
graded ethanol solutions and elimination of endogenous
peroxidase activity by incubation in 3% hydrogen peroxide
for 30 min, sections were incubated for 30 min at room
temperature in 10% normal goat serum (NGS) in Tris-
buffered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl,
pH 7.6) to reduce non-specific binding. After rinsing with
1% NGS/TBS, the sections were sequentially incubated
overnight at 4◦C with mouse anti-COX1 (Abcam, Cambridge,
MA). The sections were then incubated in goat anti-mouse
antisera (ICN), followed by species-specific peroxidase anti-
peroxidase complex (Sternberger Monoclonals and ICN).
3-3′-Diaminobenzidine (DAB) was used as a chromagen.
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Animal Surgery and Glutamate Infusion
Mice surgery and procedures approved by the IACUC at Case
Western Reserve University were performed according to the
NIH guidelines. 24 h before implantation, mini-osmotic pumps
(Model 2001, Alzet, Cupertino, CA; flow rate of 1µl/h) and brain
infusion cannula attached with catheter tubes (Brain infusion
kit 3, Alzet, Cupertino) were filled with artificial cerebrospinal
fluid (aCSF: 124 mMNaCl, 25 mMNaHCO3, 10 mMD-glucose,
2.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2 and 1 mM NaH2PO4,
adjusted to pH 7.2–7.4 using NaOH) or aCSF containing 10 mM
glutamate followed by pump incubation in phosphate buffered
saline (PBS) at 37◦C overnight. Under avertin anesthesia, a
small incision was first made in male mice to expose skull
and bregma and mini-osmotic pumps connected with catheter
were implanted subcutaneously. Then a hole was drilled in the
skull (relative to bregma: AP −0.2 mm, ML 1 mm) and the
cannula was positioned 2mm above the lateral ventricle. Another
two holes were drilled by the edge of cannula and self-tapping
bone screws (MD-1310, BASi, West Lafayette, IN) were screwed
followed by cement. Seven day after surgery, mice were deeply
anesthetized by avertin followed by spinal cord and brain tissue
collection.
Statistical Analysis
All data are presented asmean± sem. Data are analyzed by either
student-t-test or one-way ANOVA followed by Tukey’s multiple
comparison test. Statistical difference was considered significant
if p< 0.05.
Results
Reduced Expression of Miro1 in Spinal Cords of
sALS Patients
We first investigated the expression of Miro1 in spinal cord
tissues from 8 ALS patients and 6 age-matched normal subjects.
Immunoblot analysis revealed that Miro1 protein levels were
dramatically reduced in ALS spinal cords compared to age-
matched control spinal cords (Figure 1A). No significant
changes in overall mitochondrial content were noted between
ALS and control samples as evidenced by the constant
expression levels of the mitochondrial marker VDAC1
(Figure 1A). We further performed immunocytochemical
analysis of mitochondrial distribution in motor neurons
using a specific antibody against mitochondrial marker,
cytochrome c oxidase subunit 1 (COX-1). Consistent with
the previous study showing impaired mitochondrial transport
in ALS (Sasaki and Iwata, 1996), COX-1 immunoreactive
mitochondria were only present in soma and depleted in
the neurites of spinal cord motor neurons of ALS patients,
compared to the uniform distribution of Cox-1 throughout
the soma and neurites of age-matched control motor neurons
(Figure 1B).
Reduced Expression of Miro1 in Spinal Cords but
not Brains of SOD1G93A Transgenic Mice
Since the widely used transgenic mice expressing ALS-
associated SOD1 G93A mutant (SOD1G93A mice) develop
FIGURE 1 | Expression of Miro1 in spinal cords of ALS patients.
(A) Representative immunoblot and quantification analysis of Miro1 expression
in thoracic spinal cord tissues from sporadic ALS (sALS) patients (n = 8) and
age-matched control subjects (n = 6). Equal protein amounts (10 µg) were
loaded and confirmed by GAPDH. VDAC1 was used as a mitochondrial specific
marker. (B) Representative immunocytochemistry of mitochondrial marker COXI
in lumbar spinal cords of sALS patients and age-matched control subjects.
Arrowheads denote representative COX1 staining in motor neurons. Data are
means ± sem. Statistics: student t test. ∗∗p < 0.01, compared with control
subjects.
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FIGURE 2 | Expression of Miro1 in spinal cords and brains of SOD1G93A
mice. Representative immunoblot and quantification analysis of Miro1
expression in spinal cord (A) and brain (B) of 60 day old SOD1 G93A mice and
age-matched non-transgenic mice (NTG). N = 3 male mice/group. Equal protein
amounts (10 µg) were loaded and confirmed by GAPDH. VDAC1 was used as
a mitochondrial specific marker. Experiments were repeated three times. Data
are means ± sem. Statistics: student t test. ∗p < 0.05, compared with control
subjects. ns, non-significant.
phenotypes closely mimicking fALS and sALS, we next
studied the expression of Miro1 in the spinal cord and
brain tissues from these mice. Previous studies showed
that ALS disease progression went through different stages
ending in paralysis in SOD1G93A mice, with phenotype
only evident after 90 days of age (Kong and Xu, 1998).
Compared with age matched control non transgenic mice
(NTg mice), the expression of Miro-1 in spinal cords was
decreased significantly even in 60 day old SOD1G93A
mice, well preceding the onset of any disease stage
(Figure 2A). Surprisingly, unlike what we observed in the
spinal cord tissues, the Miro1 level in brains of SOD1G93A
mice remained unchanged and was similar to NTg mice
(Figure 2B).
Reduced Expression of Miro1 in Spinal Cords but
not Brains of TDP-43M337V Transgenic Mice
Autosomal dominant mutations in TDP-43 are associated
with both sporadic and familial ALS (Kabashi et al., 2008;
Sreedharan et al., 2008). We further sought to investigate
the expression of Miro1 in transgenic mice expressing
ALS-associated TDP-43 M337V mutant (TDP-43M337V
mice). Interestingly, Miro1 was also found to be greatly
reduced in spinal cords of TDP-43M337V mice when
compared with age matched control NTg mice or transgenic
mice expressing wild type TDP-43 (TDP-43WT mice)
(Figure 3A). As we found in the SOD1G93A mice, brain
samples of TDP-43M337V mice also demonstrated a similar
expression level of Miro-1 to NTg or TDP-43WT mice
(Figure 3B).
Miro1 Deficiency in sALS was Recapitulated by
Treating Motor Neurons with Glutamate
Many ALS patients demonstrate elevated extracellular glutamate
levels in the spinal cord, and glutamate excitotoxicity has
been implicated in the pathogenesis of both sALS and fALS
(Rothstein, 1995; Bruijn et al., 2004; Jaiswal, 2013). We
further employed rat primary spinal cord cultured motor
neurons challenged with glutamate as a model to investigate
the potential cause of Miro1 deficiency in sALS. Primary
motor neurons (day in vitro 5: DIV 5) were treated with
different doses of glutamate (0–50 µM) for 24 h. Treatment
with glutamate resulted in a significant dose-dependent
decrease of Miro1 in spinal cord motor neurons starting
at a concentration of 5 µM (Figure 4A). A further time
course study using a sublethal dose of glutamate (25
µM) revealed that Miro1 levels were decreased within 2
h following glutamate treatment (Figure 4B), preceding
neuronal death that was only observed 8 h later (Wang
et al., 2015) (data not shown). As expected, and consistent
with previous studies (Ackerley et al., 2000; Donnelly
et al., 2013), this glutamate-induced Miro1 reduction was
completely abolished by glutamate receptor blocker MK-801
(Figure 4C).
Frontiers in Aging Neuroscience | www.frontiersin.org 4 May 2015 | Volume 7 | Article 100
Zhang et al. Miro1 deficiency in ALS
Reduced Expression of Miro1 in Spinal Cords but
not Brains of Mice with Intraventricular
Glutamate Infusion
As glutamate caused Miro1 reduction in in vitro cultured
spinal cord motor neurons, we further attempted to confirm
this findings in spinal cord motor neurons in vivo. NTg
mice received continuous administration of a low dose of
glutamate (10 mM at a flow rate of 1µl/h) into the left
lateral ventricle via osmotic mini-pumps for 7 days. Continuous
glutamate infusion did not result in death or any histological
changes of brain, spinal cord and muscle (data not shown).
Compared with artificial cerebrospinal fluid (aCSF) infused
control mice, mice treated with glutamate demonstrated
significant reduction of Miro-1 in spinal cords (Figure 5A).
In addition, and again consistent with results observed in
SOD1G93A and TDP-43M337V mice, the expression of
Miro1 in brain tissue was unaltered by glutamate infusion
(Figure 5B).
Discussion
Here we show that the expression of Miro1 is significantly
reduced in the spinal cords of sALS patients, SOD1G93A
mice, TDP-43M337V mice and mice infused with glutamate.
An unexpected finding of this study is that Miro-1 remains
unchanged in the brains of all animal models, which
may help to explain the selective vulnerability of motor
neurons in the spinal cord. On the mechanistic level, we
demonstrated that glutamate exposure leads to dose and
time dependent decrease of Miro1 in cultured spinal cord
motor neurons, which was blocked by NMDA receptor
antagonist.
The key finding of this study is the consistent motor neuron
specific Miro1 deficiency in human disease (sALS patients), and
mouse models of ALS (SOD1G93A mice and TDP-43M337V
mice). Previous studies reported that mitochondrial movement
and distribution were impaired in ALS experimental models
(De Vos et al., 2007; Bilsland et al., 2010; Wang et al., 2013;
Magrané et al., 2014). Because Miro1 is critical for kinesin-
mediated mitochondrial movement, these findings suggest
that Miro-1 deficiency may be responsible for mitochondrial
movement deficits in ALS and ALS experimental models.
Since the expression of Miro-1 in brain is not altered by
expression of SOD1 G93A or TDP-43 M337V in mice, Miro-
1 deficiency is likely specific to motor neurons. Given the
additional fact that Miro1 is reduced in young SODG93A
mice well preceding disease onset and the fact that mice
with Miro1 deficiency show motor deficits (Nguyen et al.,
2014), all these studies together suggest that Miro-1-mediated
mitochondrial movement deficits might be the cause rather
than the consequence of ALS. It is still unclear why the
expression of Miro-1 in brains remained at a steady state in
SOD1G93A and TDP-43M337Vmice and it would be interesting
to investigate the role, if any, Miro1 plays in mitochondrial
FIGURE 3 | Expression of Miro1 in spinal cords and brains of
TDP-43M337V mice. Representative immunoblot and quantification
analysis of Miro1 expression in spinal cords (A) and brains (B) of 60 day
old male TDP-43M337V mice and age-matched NTG mice or
TDP-43WT mice. N = 3 male mice/group. Equal protein amounts (10 µg)
were loaded and confirmed by GAPDH. VDAC1 was used as a
mitochondrial specific marker. Experiments were repeated three times.
Data are means ± sem. Statistics: one-way ANOVA followed by Tukey’s
multiple comparison test. ∗∗∗p < 0.05, compared with control subjects.
ns, non-significant.
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FIGURE 4 | Expression of Miro1 in spinal cords motor neurons treated
with glutamate. (A) Representative immunoblot and quantification analysis of
the expression of Miro1 in motor neurons (DIV 5) treated with different doses of
glutamate for 24 h. (B) Representative immunoblot and quantification analysis
of the expression of Miro1 in motor neurons (DIV 5) at different time points after
25 µM glutamate treatment. (C) Representative immunoblot and quantification
analysis of the expression of Miro1 in motor neurons treated with 25 µM
glutamate and/or 20 µM MK801 for 24 h. Equal protein amounts (10 µg) were
loaded and confirmed by GAPDH. Data are means ± s.e.m. All experiments
were repeated three times. Statistics: one-way ANOVA followed by Tukey’s
multiple comparison test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, compared with
untreated control neurons.
movement or distribution in brain neurons in these mice.
Nevertheless, further studies to test whether overexpression
of Miro1 can improve mitochondrial/neuronal function and
phenotypes of either SOD1G93A or TDP-43M337V mice will
provide insights into the potential role of Miro1-mediated
mitochondrial abnormalities in the onset and progression
of ALS.
Miro1 deficiency is noted in sALS patients and mice
expressing fALS-associated SOD1G93A or TDP-43M337V,
suggesting sALS and fALS may share common molecular
processes through Miro1 deficiency. One such candidate process
may be either elevated glutamate or problems in both glutamate-
receptor and glutamate-transporter systems that have been
repeatedly reported in many cases of sALS and fALS (Rothstein,
1995; Bruijn et al., 2004; Jaiswal, 2013). Indeed, in this study
we found Miro1 clearly decreased in cultured spinal cord motor
neurons treated with glutamate. Consistently, in vivo glutamate-
induced Miro1 deficiency also occurs in spinal cords, but not
brains, of mice infused with glutamate. These results provide
direct support for the hypothesis that glutamate excitotoxicity
might be the cause of Miro1 deficiency in sALS. Some previous
studies revealed that either glutamate transporters or glutamate-
transport activities were reduced in transgenic mice expressing
ALS-associated SOD1 mutants, indicating the involvement
of glutamate excitotoxicity in mediating ALS-mutant SOD1
neuronal toxicity (Bruijn et al., 1997; Bendotti et al., 2001;
Warita et al., 2002; Boston-Howes et al., 2006; Yamanaka et al.,
2008). Therefore, glutamate excitotoxicity might be a common
mechanism leading to Miro1 deficiency in both sALS and fALS.
SOD1 is present on mitochondria (Kawamata and Manfredi,
2010). It is also possible that SOD1 might directly interact with
mitochondrial movement machinery to regulate mitochondrial
movement and distribution.
Increasing evidence suggest a critical role of mitochondria in
the pathogenesis of ALS and other neurodegenerative diseases
including Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease (Shi et al., 2010; Su et al., 2010; Archer, 2013).
The proper intracellular distribution of mitochondria adapting
to localized bioenergetic requirement is critical for cellular
physiology (Frazier et al., 2006). As Miro1 is essential for
the regulation of mitochondrial mobility, the Miro1 deficiency
observed in this study in in vivo and in vitro models of ALS
and in human disease tissue, is likely a major mediator for
impaired mitochondrial movement and distribution in ALS.
The suppression of Miro1 reduction might be a potential novel
therapeutic approach worthy of continued investigation and
validation in ALS experimental models.
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